Juniper Pharmaceuticals (NASDAQ: JNP) and Opko Health (NASDAQ:OPK) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.
This table compares Juniper Pharmaceuticals and Opko Health’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk and Volatility
Juniper Pharmaceuticals has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Opko Health has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.
This is a summary of current recommendations for Juniper Pharmaceuticals and Opko Health, as provided by MarketBeat.com.
||Strong Buy Ratings
Juniper Pharmaceuticals presently has a consensus price target of $23.00, indicating a potential upside of 283.33%. Opko Health has a consensus price target of $14.21, indicating a potential upside of 180.91%. Given Juniper Pharmaceuticals’ higher possible upside, analysts clearly believe Juniper Pharmaceuticals is more favorable than Opko Health.
Valuation and Earnings
This table compares Juniper Pharmaceuticals and Opko Health’s gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Juniper Pharmaceuticals has higher earnings, but lower revenue than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than Juniper Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
36.4% of Juniper Pharmaceuticals shares are held by institutional investors. Comparatively, 22.9% of Opko Health shares are held by institutional investors. 7.2% of Juniper Pharmaceuticals shares are held by insiders. Comparatively, 40.2% of Opko Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Juniper Pharmaceuticals beats Opko Health on 8 of the 14 factors compared between the two stocks.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.
Opko Health Company Profile
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.